Spots Global Cancer Trial Database for nis
Every month we try and update this database with for nis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Expression of NIS Protein and mRNA in Thyroid Tumors | NCT00459498 | Tumors | 18 Years - 80 Years | University of Sao Paulo | ||
| A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment | NCT06311383 | Breast Cancer | First-line Ribo... First-line endo... First-line chem... | 18 Years - | Novartis | |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | NCT05541341 | Diffuse Large B... Acute Lymphobla... Follicular Lymp... | tisagenlecleuce... | - 100 Years | Novartis | |
| A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer | NCT06075758 | Breast Cancer | ribociclib | 18 Years - 100 Years | Novartis | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | NCT05376579 | Active Secondar... | siponimod | 18 Years - 60 Years | Novartis | |
| LUMINIST: LUng Cancer Molecular Insights Non Interventional Study | NCT02300831 | NSCLC | Data Collection | - | AstraZeneca | |
| A Post Marketing Surveillance on Piqray in Korea | NCT05293470 | Breast Cancer | Piqray | 18 Years - | Novartis | |
| A Post Marketing Surveillance on Piqray in Korea | NCT05293470 | Breast Cancer | Piqray | 18 Years - | Novartis | |
| A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia | NCT06148506 | HR+HER2- Advanc... | Ribociclib Combination che... | 18 Years - 99 Years | Novartis | |
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | NCT05376579 | Active Secondar... | siponimod | 18 Years - 60 Years | Novartis | |
| A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia | NCT06148506 | HR+HER2- Advanc... | Ribociclib Combination che... | 18 Years - 99 Years | Novartis | |
| A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting | NCT04967248 | Hormone Recepto... | Alpelisib Fulvestrant | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
